<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005162A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005162</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13915941</doc-number><date>20130612</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>205</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>C</subclass><main-group>57</main-group><subgroup>15</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>205</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>C</subclass><main-group>57</main-group><subgroup>15</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>51421017</main-classification><further-classification>548953</further-classification></classification-national><invention-title id="d0e43">HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13140478</doc-number><date>20110617</date></document-id><parent-status>PENDING</parent-status><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US09/68143</doc-number><date>20091216</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13915941</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>61203053</doc-number><date>20081218</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>CISZEWSKI</last-name><first-name>Lech</first-name><address><city>Morristown</city><state>NJ</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only"><addressbook><last-name>DE LA CRUZ</last-name><first-name>Marilyn</first-name><address><city>Matawan</city><state>NJ</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="02" app-type="applicant" designation="us-only"><addressbook><last-name>KARPINSKI</last-name><first-name>Piotr H.</first-name><address><city>Lincoln Park</city><state>NJ</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="03" app-type="applicant" designation="us-only"><addressbook><last-name>MUTZ</last-name><first-name>Michael</first-name><address><city>Basel</city><country>CH</country></address></addressbook><residence><country>CH</country></residence></us-applicant><us-applicant sequence="04" app-type="applicant" designation="us-only"><addressbook><last-name>RIEGERT</last-name><first-name>Christian</first-name><address><city>Sierentz</city><country>FR</country></address></addressbook><residence><country>FR</country></residence></us-applicant><us-applicant sequence="05" app-type="applicant" designation="us-only"><addressbook><last-name>VOGEL</last-name><first-name>Caspar</first-name><address><city>Binningen</city><country>CH</country></address></addressbook><residence><country>CH</country></residence></us-applicant><us-applicant sequence="06" app-type="applicant" designation="us-only"><addressbook><last-name>SCHNEEBERGER</last-name><first-name>Ricardo</first-name><address><city>Wentzwiller</city><country>FR</country></address></addressbook><residence><country>FR</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>CISZEWSKI</last-name><first-name>Lech</first-name><address><city>Morristown</city><state>NJ</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>DE LA CRUZ</last-name><first-name>Marilyn</first-name><address><city>Matawan</city><state>NJ</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>KARPINSKI</last-name><first-name>Piotr H.</first-name><address><city>Lincoln Park</city><state>NJ</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>MUTZ</last-name><first-name>Michael</first-name><address><city>Basel</city><country>CH</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>RIEGERT</last-name><first-name>Christian</first-name><address><city>Sierentz</city><country>FR</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>VOGEL</last-name><first-name>Caspar</first-name><address><city>Binningen</city><country>CH</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>SCHNEEBERGER</last-name><first-name>Ricardo</first-name><address><city>Wentzwiller</city><country>FR</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzylyazetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.</p></abstract></us-patent-application>